Ингибирование HIF-пролил 4-гидроксилаз как перспективный подход к терапии кардиометаболических заболеваний
- Авторы: Айтбаев К.А.1, Муркамилов И.Т.2,3, Фомин В.В.4
-
Учреждения:
- Научно-исследовательский институт молекулярной биологии и медицины при Национальном центре кардиологии и терапии Минздрава Кыргызской Республики
- Кыргызская государственная медицинская академия им. И.К. Ахунбаева
- Кыргызско-Российский Славянский университет имени первого Президента России Б.Н. Ельцина
- ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
- Выпуск: Том 90, № 8 (2018)
- Страницы: 86-94
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/32805
- DOI: https://doi.org/10.26442/terarkh201890886-94
- ID: 32805
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Кубаныч Авенович Айтбаев
Научно-исследовательский институт молекулярной биологии и медицины при Национальном центре кардиологии и терапии Минздрава Кыргызской Республикид.м.н., проф., зав. лаб. патологической физиологии НИИ молекулярной биологии и медицины Бишкек, Кыргызстан
Илхом Торобекович Муркамилов
Кыргызская государственная медицинская академия им. И.К. Ахунбаева; Кыргызско-Российский Славянский университет имени первого Президента России Б.Н. Ельцина
Email: murkamilov.i@mail.ru
к.м.н., нефролог, ассистент каф. факультетской терапии Кыргызской государственной медицинской академии им. И.К. Ахунбаева Бишкек, Кыргызстан
Виктор Викторович Фомин
ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)д.м.н., член-корр. РАН, проф., зав. каф. факультетской терапии № 1, проректор по научно-исследовательской и клинической работе Первого МГМУ им. И.М. Сеченова (Сеченовский Университет) Москва, Россия
Список литературы
- Мейманалиев Т.С., Айтбаев К.А. Эпидемиология ишемической болезни сердца и частота основных факторов риска среди популяции горцев. В кн.: Болезни сердца и сердечная недостаточность в условиях горного климата. Фрунзе; 1981. С. 61-62.
- Айтбаев К.А. Уровень холестерина липопротеидов высокой плотности и других липидов крови у коренных жителей высокогорья Киргизии. Вопросы медицинской химии. 1985;(1):58-61.
- Айтбаев К.А., Мейманалиев Т.С. Распространенность атерогенных дислипопротеидемий среди горцев. Кардиология. 1992;(1):9-11.
- Айтбаев К.А., Мадаминов Я.К., Мейманалиев Т.С. и др. Исследование влияния миграции в горные регионы на систему липопротеидов крови. Космическая биология и авиакосмическая медицина. 1990;(6):45-46.
- Миррахимов М.М., Айтбаев К.А., Мураталиев Т.М. О возможности коррекции гиперхолестеринемии высокогорной тренировкой. Кардиология. 2001;(7):9-11.
- Semenza G.L, Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454. PMCID: PMC360482
- Eckle T, Kohler D, Lehmann R, et al. Hypoxia - inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008;118:166-175. doi: 10.1161/CIRCULATIONAHA.107.758516
- Ikeda J, Ichiki T, Matsuura H, et al. Deletion of phd2 in myeloid lineage attenuates hypertensive cardiovascular remodeling. J Am Heart Assoc. 2013;2:e000178.
- Rahtu-Korpela L, Karsikas S, Hörkkö S, et al. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes. 2014;63(10):3324-3333. doi: 10.2337/db14-0472
- Rahtu-Korpela L, Määttä J, Dimova E.Y, et al. Hypoxia - inducible factor prolyl 4-hydroxylase-2 inhibition protects against development of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36:608-617.
- Kaelin Jr W.G, Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393-402. doi: 10.1016/j.molcel.2008.04.009
- Myllyharju J, Koivunen P. Hypoxia - inducible factorprolyl4-hydroxylases: common and specific roles. Biol Chem. 2013;394:435-448. doi: 10.1515/hsz-2012-0328
- Semenza G.L. Regulation of oxygen homeostasis by hypoxia - inducible factor 1. Physiology (Bethesda). 2009;24:97-106. doi: 10.1152/physiol.00045.2008
- Bruick R.K, Mc Knight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340. doi: 10.1126/science.1066373
- Epstein A.C, Gleadle J.M, Mc Neill L.A, et al. C. elegans EGL-9 and mammalian homologs define a family ofdioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54. doi: 10.1016/ S0092-8674(01)00507-4
- Ivan M, Haberberger T, Gervasi D.C, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia - inducible factor. Proc Natl Acad Sci U S A. 2002;99:13459-13464. doi: 10.1073/pnas.192342099
- Berra E, Benizri E, Ginouves A, et al. HIF prolyl - hydroxylase 2 is the key oxygen sensor setting low steady - state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082-4090. doi: 10.1093/emboj/cdg392
- Loenarz C, Coleman M.L, Boleininger A, et al. The hypoxia - inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplaxadhaerens. EMBO Rep. 2011;12:63-70. doi: 10. 1038/embor.2010.170
- Appelhoff R.J, Tian Y.M, Raval R.R, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia - inducible factor. J Biol Chem. 2004;279:38458-38465. doi: 10. 1074/jbc.M406026200
- Cervera A.M, Apostolova N, Luna-Crespo F, et al. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett. 2006;233:131-138. doi: 10.1016/j.canlet.2005.03.004
- Takeda K, Ho V, Takeda H, et al. Placental but not heart defect is associated with elevated HIFα levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26:8336-8346. doi: 10.1128/ MCB.00425-06
- Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol. 2008;28:3386-3400. doi: 10.1128/MCB.02041-07
- Lee F.S, Percy M.J. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011;6:165-192. doi: 10.1146/annurev-pathol-011110-130321
- Lorenzo F.R, Huff C, Myllymäki M, et al. A genetic mechanism for Tibetan high - altitude adaptation. Nat Genet. 2014;46:951-956. doi: 10.1038/ng.3067
- Mc Donough M.A, Loenarz C, Chowdhury R, et al. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol. 2010;20:659-672. doi: 10.1016/j.sbi.2010.08.006
- Myllyharju J, Kivirikko K.I. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004;20:33-43. doi: 10.1016/j.tig.2003.11.004
- Koivunen P, Hirsilä M, Remes A.M, et al. Inhibition of hypoxia - inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem. 2007;282:4524-4532. doi: 10.1074/jbc.M610415200
- Hirsilä M, Koivunen P, Xu L, et al. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 2005;19:1308-1310. doi: 10.1096/fj.04-3399fje
- Asikainen T.M, Ahmad A, Schneider B.K, et al. Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med. 2005;38(8):1002-1013. doi: 10.1016/j.freeradbiomed.2004.12.004
- Chandel N.S, Mc Clintock D.S, Feliciano C.E, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia - inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275(33):25130-25138. doi: 10.1074/jbc.M00 1914200
- Metzen E, Zhou J, Jelkmann W, et al. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol Biol Cell. 2003;14(8):3470-3481. doi: 10.1091/mbc.E02-12-0791
- Hirsilä M, Koivunen P, Gunzler V, et al. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia - inducible factor. J Biol Chem. 2003;278(33):30772-30780. doi: 10.1074/jbc.M304982200
- Willam C, Maxwell P.H, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41(1):68-77. doi: 10.1016/j.yjmcc.2006.04.009
- Huang M, Chan D.A, Jia F, et al. Short hairpin RNA interference therapy for ischemic heart disease. Circulation. 2008;118(4):S226-S233. doi: 10.1161/CIRCULATIONAHA.107.760785
- Hyvärinen J, Hassinen I.E, Sormunen R, et al. Hearts of hypoxia - inducible factor prolyl4-hydroxylase-2 hypomorphicmice show protection against acute ischemia - reperfusion injury. J Biol Chem. 2010;285(18):13646-13657. doi: 10.1074/jbc.M109.084855
- Kerkelä R, Karsikas S, Szabo Z, et al. Activation ofhypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol Cell Biol. 2013;33(16):3321-3329. doi: 10.1128/MCB.00432-13
- Hölscher M, Silter M, Krull S, et al. Cardiomyocyte - specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem. 2011;286:11185-11194. doi: 10.1074/ jbc.M110.186809
- Adluri R.S, Thirunavukkarasu M, Dunna N.R, et al. Disruption of hypoxia - inducible transcription factor - prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia - inducible factor-1alpha transcription factor and its target genes in mice. Antioxid Redox Signal. 2011;15(7):1789-1797. doi: 10.1089/ars.2010.3769
- Oriowo B, Thirunavukkarasu M, Selvaraju V, et al. Targeted gene deletion of prolyl hydroxylase domain protein 3 triggers angiogenesis and preserves cardiac function by stabilizing hypoxia inducible factor 1 alpha following myocardial infarction. Curr Pharm Des. 2014;20:1305-1310. doi: 10.2174/13816128113199990549
- Zieseniss A, Hesse A.R, Jatho A, et al. Cardiomyocyte - specific transgenic expression of prolyl-4-hydroxylase domain 3 impairs the myocardial response to ischemia. Cell Physiol Biochem. 2015;36:843-851. doi: 10.1159/000430260
- Aragones J, Schneider M, van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008;40(2):170-180. doi: 10.1038/ng. 2007.62
- Karsikas S, Myllymäki M, Heikkilä M, et al. HIF-P4H-2 deficiency protects against skeletal muscle ischemia - reperfusion injury. J Mol Med (Berl). 2016;94:301-310.
- Ong S.G, Lee W.H, Theodorou L, et al. HIF-1 reduces ischaemia - reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc Res. 2014;104(1):24-36. doi: 10.1093/ cvr/cvu172
- Lei L, Mason S, Liu D, et al. Hypoxia - inducible factor - dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol. 2008;28(11):3790-3803. doi: 10.1128/MCB.01580-07
- Minamishim Y.A, Moslehi J, Padera R.F, et al. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009;29(21):5729-5741. doi: 10.1128/ MCB.00331-09
- Krishnan J, Suter M, Windak R, et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009;9(6):512-524. doi: 10.1016/j.cmet.2009.05.005
- Takeda K, Cowan A, Fong G.H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007;116(7):774-781. doi: 10.1161/CIRCULATIONAHA.107.701516
- Takeda Y, Costa S, Delamarre E, et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature. 2011;479(7371):122-126. doi: 10.1038/nature10507
- Murry C.E, Jennings R.B, Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-1136. PMID: 3769170
- Gho B.C, Schoemaker R.G, van den Doel M.A, et al. Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 1996;94:2193-2200. PMID: 8901671
- Cai Z, Luo W, Zhan H, Semenza G.L. Hypoxia - inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci U S A. 2013;110:17462-17467. doi: 10.1073/pnas.1317158110
- Davidson S.M, Selvaraj P, He D, et al. Remote ischaemic preconditioning involves signalling through the SDF-1alpha/CXCR4 signalling axis. Basic Res Cardiol. 2013;108(50):377. doi: 10.1007/s00395-013-0377-6
- Olenchock B.A, Moslehi J, Baik A.H, et al. EGLN1 inhibition and rerouting of alpha - ketoglutarate suffice for remote ischemic protection. Cell. 2016;164(5):884-895. doi: 10.1016/j.cell.2016.02.006
- Martin-Puig S, Tello D, Aragones J. Novel perspectives on the PHD-HIF oxygen sensing pathway in cardioprotection mediated by IPC and RIPC. Front Physiol. 2015;6:137. doi: 10.3389/fphys.2015.00137
- Zeng H, Chen J.X. Conditional knockout of prolyl hydroxylase domain protein 2 attenuates high fat - diet - induced cardiac dysfunction in mice. PLoS One. 2014;9:e115974. doi: 10.1371/journal.pone.0115974
- Xia Y, Gong L, Liu H, et al. Inhibition of prolyl hydroxylase 3 ameliorates cardiac dysfunction in diabetic cardiomyopathy. Mol Cell Endocrinol. 2015;403:21-29. doi: 10.1016/j.mce.2015.01.014
- Minamishima Y.A, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008;11:3236-3244.
- Moslehi J, Minamishima Y.A, Shi J, et al. Loss of hypoxia - inducible factor prolyl hydroxylase activity in cardiomyocytesphenocopies ischemic cardiomyopathy. Circulation. 2010;122(10):1004-1016. doi: 10.1161/CIRCULATIONAHA.109.922427
- Matsuura H, Ichiki T, Inoue E, et al. Prolyl hydroxylase domain protein 2 plays a critical role in diet - induced obesity and glucose intolerance. Circulation. 2013;127(21):2078-2087. doi: 10.1161/CIRCULATIONAHA.113.001742
- Van den Borst B, Schols A.M, de Theije C, et al. Characterization of the inflammatory and metabolic profile of adipose tissue in a mouse model of chronic hypoxia. J Appl Physiol. 2013;114:1619-1628. doi: 10.1152/japplphysiol.00460.2012
- Bakris G.L, Yu K-P, Leong R, et al. Effects of a novel anemia treatment, FG-4592 - an oral hypoxia - inducible prolyl hydroxylase inhibitor (HIF-PHI) on blood pressure and cholesterol in patients with chronic kidney disease. J Clin Hypertens. 2013;14:487-489.
- Olson E, Demopoulos L, Haws T.F, et al. Short - term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication - limited peripheral artery disease. Vasc Med. 2014;19:473-482. doi: 10.1177/ 1358863X14557151
- Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev. 2013;93(3):1317-1542. doi: 10.1152/physrev.00004.2012
- Lin N, Simon M.C. Hypoxia - inducible factors: key regulators of myeloid cells during inflammation. J Clin Invest. 2016;126(10):3661-3671. doi: 10.1172/JCI84426
- Minqin R, Rajendran R, Pan N, et al. The iron chelatordesferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol - fed rabbi. Free Radic Biol Med. 2005;38:1206-1211. doi: 10.1016/j.freeradbiomed.2005.01.008
- Zhang W.J, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010;235(5):633-641. doi: 10.1258/ ebm.2009.009229
- Guida E, Stewart A. Influence of hypoxia and glucose deprivation on tumournecrosis factor - alpha and granulocyte - macrophage colony - stimulating factor expression in human cultured monocytes. Cell Physiol Biochem. 1998;8:75-88. doi: 10.1159/000016272
- Bosco M.C, Puppo M, Pastorino S, et al. Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol. 2004;172:1681-1690.
- Cartee T.V, White K.J, Newton-West M, Swerlick R.A. Hypoxia and hypoxia mimetics inhibit TNF-dependent VCAM1 induction in the 5A32 endothelial cell line via a hypoxia inducible factor dependent mechanism. J Dermatol Sci. 2012;65(2):86-94. doi: 10.1016/j.jdermsci.2011. 10.003
- Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia - inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134(1):145-155. doi: 10.1053/j.gastro.2007.09.033
- Marsch E, Demandt J.A, Theelen T.L, et al. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur Heart J. 2016;37(39):2993-2997. doi: 10.1093/eurheartj/ehw156
- Liu H, Xia Y, Li B, et al. Prolyl hydroxylase 3 overexpression accelerates the progression of atherosclerosis in ApoE-/- mice. Biochem Biophys Res Commun. 2016;473(1):99-106. doi: 10.1136/jech.2010. 112938
- Ezzati M, Horwitz M.E, Thomas D.S, et al. Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population - based analysis of US counties. J Epidemiol Commun Health. 2012;66:e17. doi: 10.1136/jech.2010.112938